...
首页> 外文期刊>Marine Drugs >Angiotensin-I-Converting Enzyme (ACE) Inhibitors from Marine Resources: Prospects in the Pharmaceutical Industry
【24h】

Angiotensin-I-Converting Enzyme (ACE) Inhibitors from Marine Resources: Prospects in the Pharmaceutical Industry

机译:海洋资源的血管紧张素转换酶(ACE)抑制剂:制药行业的前景。

获取原文

摘要

Hypertension or high blood pressure is one of the major independent risk factors for cardiovascular diseases. Angiotensin-I-converting enzyme (EC 3.4.15.1; ACE) plays an important physiological role in regulation of blood pressure by converting angiotensin I to angiotensin II, a potent vasoconstrictor. Therefore, the inhibition of ACE activity is a major target in the prevention of hypertension. Recently, the search for natural ACE inhibitors as alternatives to synthetic drugs is of great interest to prevent several side effects and a number of novel compounds such as bioactive peptides, chitooligosaccharide derivatives (COS) and phlorotannins have been derived from marine organisms as potential ACE inhibitors. These inhibitory derivatives can be developed as nutraceuticals and pharmaceuticals with potential to prevent hypertension. Hence, the aim of this review is to discuss the marine-derived ACE inhibitors and their future prospects as novel therapeutic drug candidates for treat hypertension.
机译:高血压或高血压是心血管疾病的主要独立危险因素之一。血管紧张素I转换酶(EC 3.4.15.1; ACE)通过将血管紧张素I转化为有效的血管收缩剂血管紧张素II在调节血压方面发挥重要的生理作用。因此,抑制ACE活性是预防高血压的主要目标。最近,寻找天然ACE抑制剂作为合成药物的替代品对于防止几种副作用引起了极大的兴趣,作为海洋生物的潜在ACE抑制剂,海洋生物已衍生出许多新型化合物,例如生物活性肽,壳寡糖衍生物(COS)和邻苯二酚。 。这些抑制性衍生物可以被开发为具有预防高血压潜力的保健食品和药物。因此,本综述的目的是讨论海洋来源的ACE抑制剂及其作为治疗高血压的新型治疗药物的未来前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号